Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Syfovre
Pharma
Apellis' weak quarter could signal Syfovre 'nadir': analysts
Apellis' geographic atrophy med Syfovre may have hit a performance “nadir” in 2024’s third quarter, one group of analysts contends.
Fraiser Kansteiner
Nov 5, 2024 3:41pm
Astellas pulls application for Izervay after talks with CHMP
Oct 28, 2024 11:07am
Novartis, Apellis roll out rival datasets in rare kidney disease
Oct 28, 2024 10:03am
Apellis hit with yet another eye drug snub in Europe
Sep 20, 2024 10:06am
Watch out, Novartis. Apellis scores major win in kidney diseases
Aug 8, 2024 2:28pm
CHMP rejects Apellis' Syfovre, says yes to Merck's Winrevair
Jun 28, 2024 11:59am
